Online Program

280625
HPV vaccination motivesof young men receiving dose one in tandem with a female sex partner


Monday, November 4, 2013 : 11:00 a.m. - 11:15 a.m.

Tom Collins, BS, Rural Cancer Prevention Center, University of Kentucky, Lexington, KY
Lindsay Stradtman, MPH, College of Public Health, University of Kentucky, Lexington, KY
Nebraska Jones, Rural Cancer Prevention Center, University of Kentucky, Hazard, KY
Grace Jones, MS, APRN, College of Public Health, University of Kentucky Rural Cancer Prevention Center, Hazard, KY
Robin C. Vanderpool, DrPH, CHES, Department of Health Behavior, University of Kentucky College of Public Health, Lexington, KY
Elisia Cohen, PhD, Department of Communication, University of Kentucky College of Communications and Information Studies, Lexington, KY
Margaret McGladrey, M.A., Rural Cancer Prevention Center, University of Kentucky College of Public Health, Lexington, KY
Wallace Bates, MBA, Rural Cancer Prevention Center, University of Kentucky, Hazard, KY
Pamela Stamper, RN, Rural Cancer Prevention Center, University of Kentucky, Lexington, KY
Baretta R. Casey, MD, MPH, Department of Health Behavior, University of Kentucky College of Public Health, Lexington, KY
Richard A. Crosby, PhD, Department of Health Behavior, University of Kentucky College of Public Health, Lexington, KY
Objective: The Advisory Committee of Immunization Practices recommends the use of HPV vaccination for young males. Models suggest that by the year 2050, HPV-related cancers in men could decrease by 27% if the proposed vaccination strategies for males are successful. Unfortunately, very little is known about optimizing coverage for males. We conducted a pilot study to explore young men's post-injection motives for receiving this vaccine. Methods: Recruitment of young males (age 18-26) to accept dose one of the vaccine occurred at two campuses of a small community college. The college announced and provided free vaccination to the males reporting as a member of a couple. After consenting to participate in the study, males completed a brief survey and received dose one. Results: Data were collected from 32 males. Forty-seven percent indicated their greatest motivation for vaccination was self-protection. Twenty-five percent indicated their greatest motivation was protection of their partner, and only 1 (3%) indicated being vaccinated due to partner encouragement. Knowledge of HPV causing genital warts was associated with reporting self-protection as the greatest motivation for vaccination (p=.04). Age (p=.32), number of lifetime sex partners (p=.84), and knowledge of HPV-associated maladies (p=.33) were not associated with the motive of self-protection. Conclusion: Among college-age males presenting themselves as part of a heterosexual couple, the most common motive for HPV vaccination was self-protection. Only fear of genital warts was associated with this motive. Further studies, and vaccine promotion efforts for this population should capitalize on men's motive to avoid contracting genital warts.

Learning Areas:

Implementation of health education strategies, interventions and programs
Planning of health education strategies, interventions, and programs

Learning Objectives:
Assess the motivational affect of female partners on male uptake of HPV vaccination. Identify prioritized motivations for male uptake of HPV vaccination.

Keyword(s): Cancer Prevention, Male Health

Presenting author's disclosure statement:

Qualified on the content I am responsible for because: I have served as the associate director of the UK Rural Cancer Prevention Center for the past 3 years and in that capacity oversee the design and implementation of research projects focused on decreasing cancer risks by increasing cancer screenings and behavior change. One area of our research is decreasing cancer risks associated with HPV, by promoting HPV vaccination.
Any relevant financial relationships? No

I agree to comply with the American Public Health Association Conflict of Interest and Commercial Support Guidelines, and to disclose to the participants any off-label or experimental uses of a commercial product or service discussed in my presentation.

Back to: 3167.0: New research on HPV